



## Implanet announces its 2020 financial calendar

**Bordeaux, Boston, December 4 , 2019:** IMPLANET (Euronext Growth: ALIMP, FRO010458729, eligible for PEA-PME equity savings plans; OTCQX: IMPZY), a medical technology company specializing in vertebral and knee-surgery implants, today announces its schedule for the publication of financial information for 2020.

Event	Dates*
2019 Full-Year Annual Revenue	January 21, 2020
2019 Full-Year Results	February 24, 2020
Annual General Meeting	April 7, 2020
2020 First-Quarter Revenue	April 21, 2020
2020 First-Half Revenue	July 7, 2020
2020 First-Half Results	September 15, 2020
2020 Third-Quarter Revenue	October 13, 2020

(\*): These dates can be subject to modifications. Press releases will be published after market close.

**Next financial press release:** 2019 annual revenue, on Tuesday January 21<sup>st</sup>, 2020 (after market)

### About Implanet

Founded in 2007, Implanet is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its activity is based on 2 main product ranges, the JAZZ® latest-generation implant, aimed at treating spinal pathologies requiring vertebral fusion surgery and MADISON, its implant for first-line knee prosthesis surgery. Implanet's tried-and-tested orthopedic platform, which is based on perfect control over the traceability of its products, provides it with a proven ability to promote these innovations. Protected by four families of international patents, JAZZ® and MADISON have obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE marking. Implanet employs 38 staff and recorded 2018 revenue of €6.7 million. For further information, please visit [www.Implanet.com](http://www.Implanet.com). Based near Bordeaux in France, Implanet established a US subsidiary in Boston in 2013. Implanet is listed on Euronext™ Growth market in Paris. The Company would like to remind that the table for monitoring the equity line (OCA, OCAP, BSA) and the number of shares outstanding, is available on its website: <http://www.Implanet-invest.com/suivi-des-actions-80>

### Contacts

#### IMPLANET

Ludovic Lastennet, CEO  
David Dieumegard, CFO  
Tel.: +33(0)5 57 99 55 55  
[investors@Implanet.com](mailto:investors@Implanet.com)

#### NewCap

Investor Relations  
Sandrine Boussard-Gallien  
Tel.: +33 (0)1 44 71 94 94  
[Implanet@newcap.eu](mailto:Implanet@newcap.eu)

#### NewCap

Media Relations  
Nicolas Merigeau  
Tel.: +33 (0)1 44 71 94 94  
[Implanet@newcap.eu](mailto:Implanet@newcap.eu)